CanSino Biologics Inc. (CANSINOBIO) reported no changes in either authorised or issued share capital for the month ended 31 May 2026, maintaining balance-sheet stability across both its Hong Kong-listed H shares and Shanghai STAR Market-listed A shares.

Authorised and Issued Share Capital • Authorised/registered share capital remained unchanged at RMB 247.04 million, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1. • Issued share counts were likewise stable: 132.67 million H shares and 114.37 million A shares. The company held no treasury shares at month-end.

Public Float Compliance • The exchange-mandated public float threshold—minimum 5% for PRC issuers with other listed shares—was comfortably met for the H-share class as at 31 May 2026.

Equity Incentive Programmes • H-share options: 860,000 options remain outstanding under the “2025 Core Management H Share Option Scheme” adopted on 23 October 2025. No options were exercised or lapsed during May; potential dilution from this scheme stands at 860,000 new H shares. • A-share restricted stock: Under the “2025 Restricted A Share Incentive Scheme” (approved 23 October 2025), a total of 2.05 million A shares can still be issued. No restricted shares were granted or vested in May.

Aggregate Potential Dilution • Combined, the two incentive plans could add up to 2.91 million new shares—about 1.18 % of CANSINOBIO’s current total issued share base of 247.04 million shares—if all options are exercised and all restricted shares are vested.

Capital Structure Outlook With no share repurchases, cancellations, or new issuances during the month, CANSINOBIO’s capital structure remains unchanged. The existence of unexercised options and unissued restricted shares provides flexibility for future talent incentives but poses only modest potential dilution relative to the company’s overall share count.